Updated time: 2021-09-28 15:20:24
11A-1070201
Acute myocardial infarction is a significant health problem. Reperfusion is the only clinical strategy to salvage ischemic myocardium but it also causes additional damage. To date there are no established managements for reducing the acute myocardial ischemia/reperfusion (I/R) injury. Activation of protein tyrosine phosphatases (PTPs) during I/R results in cardiac damage. This invention disclosure a clinical drug Auranofin significantly reduces the I/R damage through inhibiting PTPs and modulating the PTPs-related pathways. We propose that auranofin could be a novel medication for attenuating myocardial I/R injury in clinical patient management.
- Auranofin could significantly reduce the cardiac injury caused by acute myocardial ischemia/reperfusion process
Clinical management for patients presented with acute myocardial infarction
- Basic researches for investigating the mechanisms of cardioprotection
Tzu-Ching Meng, Chiu-Fen Yang, Michael Yu-Chih Chen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

The application of auranofin in attenuating acute myocardial ischemia/reperfusion injury